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Canine Hepatic Neuroendocrine Carcinoma: An
Immunohistochemical and Electron Microscopic Study
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P. J. BERGMAN
Department of Pathology, The Animal Medical Center, New York, NY (AKP, SJN1); Animal Health Trust, Lanwades
Park, Suffolk, UK (TS); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (RAE, CA);
and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, New York, NY (DC, PJB)
Abstract. Ten dogs with neuroendocrine carcinoma of the liver were selected for inclusion in the study.
Clinical signs were anorexia (7), vomiting (5), polydipsia/polyuria (3), icterus (2), lethargy (2), weight loss (2),
paresis (1), ataxia (1), weakness (1), collapse (1), and urinary tract infection (1). Hematologic and biochemical
abnormalities included anemia (2/8), leukocytosis (4/8), high liver enzyme activity (serum alkaline phosphatase,
7/9; alanine transaminase, 7/9; aspartate transaminase, 8/9), and high total bilirubin (6/9). Grossly, the tumors
were diffuse, involving all liver lobes in six dogs, and two dogs had various-sized nodules in addition to diffuse
involvement. Histologically, there were eight tumors with solid or trabecular pattern (group A), one tumor with
cords or rows of neoplastic cells (group B), and one tumor with multiple rosette-like structures (group C).
Immunohistochemical studies revealed that all 10 neoplasms were positive for at least one of the endocrine
markers used: neuron-specific enolase (NSE; 8/10), synaptophysin (5/10), and chromogranin-A (3/10). A panel
of NSE, chromagranin-A, and synaptophysin detected 100% of the tumors in our series. Electron microscopy
confirmed the diagnosis by the presence of intracytoplasmic neurosecretory granules in the two examined cases.
Our results show that neuroendocrine markers commonly used in humans can be used for the diagnosis of
hepatic neuroendocrine carcinoma in dogs, preferably a panel of synaptophysin, chromagranin-A, and NSE
because chromogranin-A alone is not as useful in dogs as in humans.
Key words: Canine; electron microscopy; immunohistochemistry; liver; neuroendocrine carcinoma.
Neuroendocrine cells, which produce peptides and
amines, are distributed in many organs and tis-
sues.3,9,22,28 The most common sites are the respiratory
and digestive tracts. In the past, these cells were called
‘‘APUD’’ (amine precursor uptake and decarboxyl-
ation) cells. They were thought to be neuroectodermal
in origin, arising from the neural crest.18,19 At present,
these neuroendocrine cells, especially the epithelial-as-
sociated cells, are considered to be endodermal in or-
igin and are designated as diffuse endocrine system.9,22
The term ‘‘carcinoid’’ was coined by Oberndorfer
in 1897 to distinguish a group of mostly benign, small
intestinal tumors from aggressive adenocarcinomas.
Although the terms carcinoid and ‘‘neuroendocrine
carcinoma’’ are interchangeably used, the latter term
is considered more appropriate.10,25
The clinicopathologic spectrum of neuroendocrine
tumors ranges from the benign carcinoid to the ag-
gressive neuroendocrine carcinoma. These tumors are
seen in a wide range of organs in humans but have
1 Present address: Department of Pathology, College of
Veterinary Medicine, University of Tennessee, Knoxville,
TN.
rarely been described in domestic animals.3,9,13,16,22,25
Neuroendocrine tumors arise from the diffuse neuro-
endocrine system.9 In humans, the gastropancreatic
and bronchopulmonary organs are the most common
sites.3,9,22,25,26 Primary neuroendocrine carcinoma of the
liver is rarely reported, but single cases in middle-aged
females predominate.2,6–8,21 Histologically, neuroendo-
crine carcinomas of the liver in humans are described
as having cords, trabeculae, or glandular (rosette-like)
patterns.15 Most of them stain with Grimelius silver
stain. Immunohistochemically, they consistently ex-
press chromogranin-A, NSE, and synaptophysin, and
occasionally cytokeratin, somatostatin, serotonin, and
other peptides.2,6,8 Ultrastructurally, these tumors have
40–100 m intracytoplasmic neurosecretory gran-
ules.2,6,8
Neuroendocrine carcinomas have rarely been de-
scribed in dogs and cats. The sites include the intes-
tines,17 esophagus,13 nasal cavity,11 skin,17 bile duct,12
gallbladder,29 liver,15 and, more recently, the nasophar-
ynx.16
The first detailed reports of primary hepatic neuro-
endocrine carcinoma in dogs were published in 1980
and 1981.14,15 A summary of findings from these pre-
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Fig. 1. Liver; canine. Neuroendocrine carcinoma with tra-
becular cell arrangement. HE. Bar  217 m.
Fig. 2. Liver; canine. Neuroendocrine carcinoma with
cells arranged in rows. HE. Bar  217 m.
Fig. 3. Liver; canine. Neuroendocrine carcinoma with
cells arranged in rosettes. HE. Bar  217 m.
vious studies showed that 14% (15/110) of primary
hepatic neoplasms, exclusive of tumors of nonepithe-
lial origin, were considered to be of neuroendocrine
origin because of their clinical, morphologic, and bi-
ologic distinctions from the hepatocellular and cholan-
giocarcinomas in the same series. All the tumors in
that series stained positively with Grimelius silver
stain. Most of the dogs (71%) were under 10 years of
age, and there was no sex or breed predilection. High
white blood cell count, low hemoglobin, and higher
than normal values for liver function tests were com-
mon. Grossly, all liver lobes were involved in 10 dogs
with diffuse disease; in the other dogs, the livers were
not enlarged, and the lesions were nodular.
The morphologic patterns were similar to those re-
ported in humans with neuroendocrine carcinoma,2,7,9,15
and three distinct patterns were observed: 1) solid
groups of cells with fibrovascular stroma, 2) groups or
cords of cells with fibrovascular stroma, and 3) alve-
olar pattern with multiple rosette-like structures and
fibrovascular stroma. Peritoneal carcinomatosis and
metastasis to regional lymph nodes were the most
common extrahepatic manifestations in most of the
dogs.15 Immunohistochemistry and electron micros-
copy were not done in this series.
A literature survey done from 1980 shows only one
case of hepatic carcinoid in a dog, which had hyper-
corticism and hypokalemia.4 Another case report de-
scribes a neuroendocrine carcinoma in the gallbladder
of a dog.29 Single cases of neuroendocrine carcinoma
in the liver and extrahepatic bile duct have been de-
scribed in a study of 47 nonhematopoietic neoplasms
of the hepatic and biliary systems of cats.12
In this study, we describe the clinical, histologic,
and immunohistochemical findings in 10 cases and
electron microscopic findings in two cases of hepatic
neuroendocrine carcinoma in dogs.
Materials and Methods
Ten cases of neuroendocrine carcinoma of the liver in
dogs were selected from the pathology department files of
The Animal Medical Center. Signalment, results of hema-
tologic and biochemical testing, gross pathologic findings,
and follow-up information were collected from the medical
and pathology records. All the available slides were exam-
ined to confirm the diagnosis and primary location. Only
cases in which adequate slides were available to confirm
neuroendocrine carcinoma of the liver were included in the
study. All tissues had been fixed in 10% buffered formalin,
routinely processed, and stained with hematoxylin and eosin.
Morphologically, the neoplasms were divided into three
histologic groups on the basis of previously described pat-
terns of neuroendocrine carcinoma in humans and dogs.15,16,25
In cases in which more than one pattern was observed, the
predominant component determined the tumor group. In
brief, the morphologic groups as described are as follows.
Group A tumors consist of solid groups or nests of neoplas-
tic cells separated by fibrovascular stroma, often with a per-
itheliomatous arrangement of peripheral cells. The cells are
round to polygonal, with granular eosinophilic cytoplasm
and vesiculated nuclei with prominent nucleoli (Fig. 1).
Group B tumors consist of cords of neoplastic cells separated
by fibrovascular stroma (Fig. 2). Group C tumors consist of
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Table 1. Antibodies and the dilutions used for immunohistochemical studies of neuroendocrine carcinoma of the liver
in 10 dogs. Primary antibody incubation periods were 30 minutes.
Antiserum Supplier (Biogenex) Antigen Retrieval Final Antibody Concentration
Chromogranin-A Clone LK2H10 pH 9.5 40 g/ml, 1 : 200
Synaptophysin Clone 5np88 None 500 g/ml, 1 : 100
Cytokeratin AE1/AE3 Trypsin 70 g/ml, 1 : 100
Neuron specific Ready to use None 10 g/ml
S-100 Clone 15E2E2 pH 6 0.31 g/ml, 1 : 3,200
Glucagon pH 6 1 : 100
Serotonin pH 6 42 g/ml, 1 : 400
Insulin None 34 g/ml, 1 : 500





Tested Mean SD Median Range
RBC 5–8 8 6.1 1.332328 6.715 4.3–7.62
WBC 6–17 8 20.54 13.98764 17.95 5.3–46
ALP 10–50 9 1,290 1,626.6 598 27–4,900
Total bilirubin 0.1–0.6 9 2.06 3.242784 0.8 0–7.8
AST 5–65 9 569.2 1,002.409 157 21–3,160
ALT 5–75 9 1,138.8 1,629.905 415 25–4,750
LDH 20–250 6 292.33 236.9935 207 106–728
Total protein 5.1–7.8 9 5.43 0.795997 6.1 4.9–7.4
* RBC  red blood cells; WBC  white blood cells; ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate
aminotransferase; LDH  lactic dehydrogenase.
groups of acinar or rosette-like structures, enclosed in similar
stroma, and lined by cuboidal or columnar cells (Fig. 3).
Selected slides from each case were immunohistochemi-
cally stained using a computer-controlled automated system
(Optimax Plus, Biogenex Laboratories, San Ramon, CA),
within the Flaherty Comparative Oncology Laboratory at the
Animal Medical Center. Antigen-retrieval pretreatment was
carried out either by heating the tissue sections in buffered
solutions (pH 6.0 or 9.5) or by enzymatic proteolytic diges-
tion with trypsin (Table 1). Tissue sections were treated with
3% hydrogen peroxide, washed in buffer, and avidin and
biotin block applied (Biocare Medical, Walnut Creek, CA).
Sections were incubated with the primary antibody for 30
minutes at room temperature. Chromagen staining was
achieved by use of a modified, biotin-streptavidin amplified
detection system (Biogenex Laboratories), and color was de-
veloped by 3,3-diaminobenzidine. Sections were then coun-
terstained with hematoxylin. Negative controls were pro-
duced by replacing the primary antibody with polyclonal
rabbit antisera raised against an irrelevant antigen (negative-
control sera, Biogenex Laboratories). Paraffin-embedded ar-
rays containing different canine tissues (specifically pancre-
atic islets, stomach, adrenal medulla, and skin) were used as
controls to ensure correct positive and negative expression.
A list of the antibodies used and their dilutions is given in
Table 1.
Immunohistochemically processed slides (for which at
least one of the endocrine markers was positive) were eval-
uated by two of the authors (AP and SJN) both individually
and jointly. The degree of expression was graded as 0, 1,
2, or 3 on the basis of the approximate number of cells
that were expressing the antigen of interest—grade 3, more
than 50% of the cells positive; grade 2, 25–50% of the
cells positive; grade 1, less than 25% or rare cells positive;
and zero, when there was no observed staining.
Tissues for electron microscopy were fixed in a buffered
(pH 6) formaldehyde and gluteraldehyde mixture and pro-
cessed according to standard procedures.
Results
Ten dogs were included in this study. The number
of males and females was equal. Breeds represented
included mixed breed (3), Boxer (2), Dalmatian (1),
Doberman (1), Golden Retriever (1), Shetland Sheep-
dog (1), and Poodle (1). The age range was 3–16 years
(median age, 10 years and mean age, 9.8 years). Clin-
ical signs included: anorexia (7), vomiting (5), poly-
dipsia/polyuria (3), lethargy (2), weight loss (2), pa-
resis (1), ataxia (1), weakness (1), and collapse (1).
Associated conditions included: icterus (2) and urinary
tract infection (1).
Results of hematologic and biochemical testing are
given in Table 2. Abnormalities included anemia (2/
8), leukocytosis (4/8), high liver enzyme activity (se-
rum alkaline phosphatase, 7/9; alanine transaminase,
7/9; aspartate transaminase, 8/9), and high total bili-
rubin (6/9). High lactate dehydrogenase and low plas-
ma proteins were each seen in one dog (1/9).
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Table 3. Results of immunohistochemical studies in 10 dogs with neuroendocrine carcinoma of the liver.*
Case No. Syn NSE Chr-A Serotonin Insulin
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
Total number of cases positive 5 8 3 3 1
* Syn  Synaptophysin; NSE  neuron-specific enolase; Chr-A  Chromagranin-A.
All 10 dogs were euthanatized soon after diagnosis
(1–8 days; mean, 3 days). In six dogs, the tumors were
described grossly as diffuse, involving all liver lobes,
with no nodular lesions. In two dogs, the liver had
various-sized nodules in addition to diffuse involve-
ment. In the other two dogs, gross descriptions were
not available. Histologically, there were eight group A
tumors (solid), one group B tumor (cords or rows of
neoplastic cells), and one group C tumor (multiple ro-
sette-like structures).
The results of immunohistochemical studies are giv-
en in Table 3. None of the neoplasms expressed AE1/
AE3, S-100 protein, glucagon, or gastrin. All 10 neo-
plasms were positive for at least one of the endocrine
markers used: NSE (8/10, Fig. 4), synaptophysin (5/
10, Fig. 5), and chromagranin-A (3/10, Fig. 6). One
neoplasm expressed all the three markers. Three neo-
plasms stained only for NSE and one only for chrom-
agranin-A. In addition, three neoplasms stained for se-
rotonin (3/10) and one for insulin (1/10).
Electron microscopy showed that both neoplasms
had conspicuous, intracytoplasmic, dense-core neuro-
secretory granules, which ranged from round (Fig. 7)
to pleomorphic (Fig. 8). Both showed epithelioid mor-
phology, closely opposed cell membranes, and contin-
uous basement membrane. The nuclei were round or
slightly irregular, with small nucleoli.
Discussion
One additional case of hepatic neuroendocrine car-
cinoma in the dog4 has been described since 1980,
when the first studies of this tumor were published.14,15
This group of hepatic tumors, about 14% of the pop-
ulation of hepatic neoplasms in the 1980 study, may
be underreported or less well recognized; and possibly
these neoplasms are being diagnosed as cholangiocar-
cinoma or hepatocellular carcinoma. However, the dis-
tinct morphologic features of neuroendocrine carci-
noma distinguish it from other epithelial neoplasms of
the liver. The signalment of the 10 dogs of this study
was similar to that of the 1980 group, but because we
had no reference population for the dogs of this study,
this comparison cannot be validated.14,15 Immunohis-
tochemical studies were not reported in the 1980 study,
but in all cases, the presence of neurosecretory gran-
ules was confirmed by use of modified Grimelius sil-
ver stain.
Immunohistochemical studies of hepatic neuroen-
docrine carcinoma of dogs have not been done, except
for a single case report, in which none of the antibod-
ies used were positive.4 Results of this study reveal
that the commonly used neuroendocrine markers for
neuroendocrine carcinoma in humans, synaptophysin,
NSE, and chromagranin-A, can also be used to distin-
guish these tumors in dogs. All 10 neoplasms were
positive for at least one of three markers (Table 3).
Eight of 10 and five of 10 were positive for NSE and
synaptophysin, respectively. Only three of 10 were
positive for chromogranin-A, and only three of 10
were positive for serotonin; but when the results for
serotonin and insulin (1/10) were included, most of the
tumors in this series (6/10) expressed more than two
peptides or amines. The possibility that insulin and
serotonin expression in a small percentage of tumors
might represent metastatic tumor from primary pan-
creatic neoplasms was excluded by examination of
surgical records and histopathologic samples. Chrom-
ogranin-A, which is one of the most common antibod-
ies used as an endocrine marker in humans,3,9,21 is less
useful than synaptophysin and NSE in dogs and
cats.13,16,17 A combination of neuroendocrine markers
would be a better choice than chromagranin-A alone,
in these species. A panel of NSE, chromagranin-A,
and synaptophysin detected 100% of the tumors in this
series, whereas combinations of NSE and synaptophy-
sin or NSE and chromagranin-A detected 90% of cas-
es, respectively.
In this series, none of the tumors expressed AE1/
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Fig. 4. Liver; canine. Neuroendocrine carcinoma cells
demonstrating positive expression for neuron-specific eno-
lase (NSE). Avidin–biotin–peroxidase complex method, he-
matoxylin counterstain. Bar  108 m.
Fig. 5. Liver; canine. Neuroendocrine carcinoma cells
demonstrating positive immunohistochemical expression for
synaptophysin. Avidin–biotin–peroxidase complex method,
hematoxylin counterstain. Bar  108 m.
Fig. 6. Liver; canine. Neuroendocrine carcinoma cells
demonstrating positive immunohistochemical expression for
chromagranin-A. Avidin–biotin–peroxidase complex meth-
od, hematoxylin counterstain. Bar  108 m.
Fig. 7. Liver, canine. High-power electron micrograph
showing abundant, round, membrane-bound neurosecretory-
type granules with prominent halos concentrated in the elon-
gated cell processes (arrow). Uranyl acetate and lead citrate
counterstain. Bar  1 m.
Fig. 8. Liver; canine. Electron micrograph of a portion of
an epithelial cell showing a cluster of oval and pleomorph-
ically shaped, dense-core granules (arrow). Uranyl acetate
and lead citrate counterstain. Bar  1 m.
AE3. A similar observation has been made in previous
reports of neuroendocrine carcinoma in dogs and
cats.13,16,17 AE1/AE3 can possibly be used to differen-
tiate adenocarcinoma from neuroendocrine carcinoma
in dogs and cats.6
Hepatic neuroendocrine carcinoma in humans ex-
presses more peptides than was demonstrated in this
study, although the most commonly reported peptides
are chromogranin-A, chromagranin-B, NSE, synapto-
physin, serotonin, gastrin, and insulin.2,6,8,21 In humans,
high serum concentrations of NSE, chromogranin, and
5-hydroxyindole acetic acid are being used to diagnose
neuroendocrine carcinoma, and this may be contem-
plated in dogs.2,8,21 A panel of NSE, chromagranin-A,
and synaptophysin is recommended to diagnose he-
patic carcinoids in dogs because 100% of our cases
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were detected with this panel. Use of single markers
such as NSE, synaptophysin, and chromagranin-A de-
tected 80, 50, and 30%, respectively. Histologic dif-
ferentiation of hepatic neuroendocrine carcinoma from
biliary adenocarcinoma and hepatocellular carcinoma
is essential to the pathologist, and the former neoplasm
may be associated with shorter survival/euthanasia in-
tervals (mean 3 days in this study).
As to the cell of origin of hepatic neuroendocrine
carcinoma, studies of various hepatic diseases in hu-
mans and results of animal experiments suggest that
the canal of Hering harbors facultative stem cells.1,26,27
The facultative stem cells give rise to hepatocytes and
small oval cells, and the oval cells act as bipotential
progenitor cells giving rise to hepatocytes and bile
ductular cells.5 The ductular cells stain with cytoker-
atin 19, a biliary epithelial marker. The proliferating
bile ductular cells, which are intermediate cells be-
tween hepatocytes and bile ductular cells, immunohis-
tochemically express chromogranin-A, and electron
microscopic studies reveal dense-core neuroendocrine
granules.20,23,24 These pluripotent cells may be the pre-
cursor cells of neuroendocrine carcinoma in the liver.
It has been suggested that the oval cells and ductular
cells develop into hepatocellular carcinoma and cho-
langiocarcinoma.20,26 There is also growing evidence
that bone marrow stem cells may contribute to the re-
generation of hepatic cells.1,20,27
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